CRO services in cardiovascular disease (CVD)

Investigate the efficacy of your potential novel agents in
rodent models of cardiovascular disease (CVD).

Cardiac fibrosis model

  • Co-infusion of angiotensin II and phenylephrine over four weeks
  • Cardiac hypertrophy
  • Systolic and diastolic cardiac dysfunction
  • Perivascular and interstitial fibrosis
  • Characterization by echocardiography, histology, light sheet imaging and RNAseq

Atherosclerosis model

  • Genetically modified mouse models (ApoE-/- or LDL r-/-) on western diet
  • Hypercholesterolemia
  • Obesity and glucose intolerance
  • Plaque volume quantification and composition incl. 3D spatial mapping
  • “En face” plaque area quantification of the aortic arch using Oil-Red-O staining​
Publications

Fully equipped platform for cardiovascular characterization

We have a unique combination of state-of-the art in vivo, ex vivo and in vitro methodologies that can be individually combined to evaluate drug efficacy in cardiovascular diseases.

We have several established models of HFrEF. The study design can be modified to meet your exact needs.

 

Related Links:

Main offerings

 

  • State-of-the art echocardiography using a high-resolution imaging platform incl. assessment of cardiac function in 2D, 4D and strain imaging.
  • Wireless chronic acquisition of electrocardiography (ECG) using telemetry.
  • Histological evaluation of fibrotic and arteriosclerotic changes in the myocardium.
  • 3D imaging of the intact mouse heart incl. quantification of cardiac wall and cavity volumes, infarct volume and capillary density.
  • Single-cell and bulk myocardial RNA sequencing.
  • Measurement of clinically-relevant plasma markers of cardiomyocyte damage and stretch.

Get in touch

Please get in touch if you are interested in discussing how to get your study started.

Michael Feigh

Director

mfe@gubra.dk
+45 2382 9493

© 2021 Gubra